Government ministers and leading parliamentarians have expressed alarm that the United Kingdom's series of deals with Washington are "lacking a solid foundation." This comes after revelations that a so-called "milestone" deal on drug pricing, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond broad headline terms outlined by government press releases.
The arrangement concerning medicines, promoted as a "significant" achievement, remains an "statement of intent" without a signed legal text. It has been highlighted that the official announcements from the UK and US governments describe the deal in sharply different terms. The British version emphasizes securing "duty-free access" as a unique achievement, while the American announcement dwells on the expectation for the NHS to pay higher prices for new medications.
"The danger exists that the UK government has made commitments to raise drug prices in return for only a assurance from President Trump," stated David Henig, a trade policy analyst. "It is documented he has a record of not honouring his word."
Concerns have been heightened by Washington's recent decision to pause the £31bn "tech prosperity deal", which was previously heralded as "a huge leap forward" in the bilateral relationship. The US pointed to a failure to advance from the UK on lowering trade barriers as the reason for the pause.
Furthermore, concessions agreed to for British farmers as part of an earlier tariff deal have not been formally ratified by the US, despite a imminent January deadline. "We have been informed that that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.
Privately, ministers have voiced worries that the government's deals with Washington are lacking substance. One minister was quoted as stating the series of agreements as "built on sand," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."
Layla Moran, a senior MP on the health committee, stated: "The only thing more surprising than Trump's temper tantrums is the UK government's naive belief that his administration is a good faith actor. The NHS is too precious to be gambled with."
Officials have attempted to minimize the chances of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.
Officials admit that instability is part and parcel of dealing with the current US leadership. However, they argue that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.
Yet, issues have emerged in carrying out the broader trade deal. Promised quotas on beef exports have not materialized, and the pledge to "reduce steel tariffs to zero" has remains unmet, with tariffs staying at 25%.
As negotiations continue, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.
A certified nutritionist and wellness coach passionate about helping others achieve their health goals through evidence-based practices.
